Neutralization kinetics of sensitive and resistant subtype B primary human immunodeficiency virus type 1 isolates.
The aim of the study was to determine if sensitive and resistant human immunodeficiency virus type 1 (HIV-1) subtype B primary isolates have different neutralization kinetics. Neutralization assays were undertaken where either the time allowed for virus to react with antibodies or the subsequent period of this mixture's exposure to target cells were varied. The relative neutralization sensitivity/resistance is a reproducible property of the isolates. In a minority of combinations, the titre falls exponentially for as long as the free virions are exposed to antibody. In the remainder, neutralization kinetics shows deviations which may be attributed to events occurring after the virus-antibody mixture is added to the target cells: significant neutralization with minimal exposure of the free virions to antibody; a plot where reduction in virus titre is parallel to the duration of the incubation phase of the assay. Neutralization rate constants are similar for primary HIV-1 SF33, HIV-1 SF162, and HIV-1 89.6, reaching 5 x 10(5)-1 x 10(6)/M sec for the monoclonal antibody IgG1 b12. However, although increased antibody levels produced greater reductions in virus titre the rate of neutralization was not proportional to the antibody concentration. Neutralization of either the free virion or cell-associated virus does not correlate with the resistance/sensitivity of primary subtype B isolates. The target cells play an active role, so that in designing neutralization assays with primary isolates of HIV-1, events following the virus-antibody complex binding to the cell surface have to be taken into consideration.
Davis
David
D
Department of Microbiology, Virology Unit, Institute of Tropical Medicine, Nationalestraat, Antwerp, Belgium. davis@bprc.nl
Donners
Helen
H
Willems
Betty
B
Ntemgwa
Michel
M
Vermoesen
Tine
T
van der Groen
Guido
G
Janssens
Wouter
W
D000911:Antibodies, Monoclonal; D015483:HIV Antibodies; D015658:HIV Infections / Q000276:immunology / Q000821:virology; D015497:HIV-1 / Q000145:classification* / Q000276:immunology* / Q000302:isolation & purification / Q000472:pathogenicity; D006801:Humans; D066298:In Vitro Techniques; D007700:Kinetics; D009500:Neutralization Tests / Q000379:methods*; D014774:Virulence / Q000276:immunology
D000911:Antibodies, Monoclonal; D015483:HIV Antibodies